8.16
-0.16 (-1.92%)
| Previous Close | 8.32 |
| Open | 8.25 |
| Volume | 332,389 |
| Avg. Volume (3M) | 434,722 |
| Market Cap | 481,559,936 |
| Price / Book | 0.870 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Diluted EPS (TTM) | -2.77 |
| Total Debt/Equity (MRQ) | 0.33% |
| Current Ratio (MRQ) | 11.62 |
| Operating Cash Flow (TTM) | -150.21 M |
| Levered Free Cash Flow (TTM) | -87.13 M |
| Return on Assets (TTM) | -25.38% |
| Return on Equity (TTM) | -36.57% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Cullinan Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 0.5 |
| Average | 1.50 |
|
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.55% |
| % Held by Institutions | 116.27% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mpm Bioimpact Llc | 31 Mar 2025 | 7,648,268 |
| Lynx1 Capital Management Lp | 31 Mar 2025 | 3,215,722 |
| Blue Owl Capital Holdings Lp | 31 Mar 2025 | 2,435,972 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 33.00 (HC Wainwright & Co., 304.41%) | Buy |
| Median | 24.00 (194.12%) | |
| Low | 22.00 (Stifel, 169.61%) | Buy |
| Average | 26.33 (222.67%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 8.17 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 11 Jun 2025 | 22.00 (169.61%) | Buy | 8.98 |
| UBS | 12 May 2025 | 24.00 (194.12%) | Buy | 7.91 |
| HC Wainwright & Co. | 16 Apr 2025 | 33.00 (304.41%) | Buy | 7.61 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |